Core F: Biomarker Core

摘要岩心F：生物标志物岩心 生物标志物正在成为有效的临床管理和试验协调的重要组成部分 阿尔茨海默病和相关痴呆(ADRD)，并将被要求启用精准医学 诊断和治疗的方法。新增加的生物标志物核心(BC)的主要功能 密歇根州阿尔茨海默病研究中心(MADRC)将促进创新研究 已建立的和新的血液生物标记物，并提供专业知识和获得生物标记物分析技术 对于密歇根大学、密歇根州立大学、韦恩州立大学以及 其他ADRC。BC的总体目标是使用尖端的超灵敏ELISA法和定量质量 光谱(MS)方法测量血液中的生物标志物，识别和构建新的血基 生物标记物分析，并将生物标记物与疾病的临床措施相结合。我们将利用MADRC 来自实现这一目标的持续和未来努力的资源，并促进与 MADRC的中心主题是识别、理解和调节β以外的许多因素--淀粉样蛋白 为ADRD干杯。MADRC纵向队列和其他正在进行的临床研究中的不同患者群体 研究工作，加上开发新的生物标记物分析的能力，将显著提高 BC专注于关于当前和新的生物标记物的程度的独特问题的能力 目标提高了诊断的准确性，并跟踪疾病进展和随时间推移的可预测性 患者群体，包括代表性不足的种族/民族群体。卑诗省将采取以下五项措施 目标：1)提供已建立的血液生物标志物的测量；2)开发和实施新的生物标志物 分析，3)促进血液生物标志物与已建立的临床实践的集成，以促进翻译 研究，4)向国家阿尔茨海默氏症协调中心提供血液生物标记物数据，5)教育 并培训卫生保健专业人员、科学家和学生使用生物标记物分析。卑诗省的目标和 将通过与MADRC临床核心、数据管理和统计密切合作来实现目标 核心，神经成像核心，神经病理学核心，研究教育组成部分。通过这些努力， BC将显著加强由MADRC支持的研究，导致持续和重大的 对现场的影响，因为我们建立了对诊断和预测效用的全面评估 基于血液的生物标记物特征。我们还将与其他ADRC和调查人员进行接触，以帮助形成 痴呆症评估和治疗的不断发展的临床格局。

ABSTRACT – CORE F: BIOMARKER CORE Biomarkers are becoming instrumental components of effective clinical management and trial coordination for Alzheimer’s disease and related dementias (ADRD), and will be required to enable precision medicine approaches to diagnosis and treatment. The primary functions of the newly added Biomarker Core (BC) of the Michigan Alzheimer’s Disease Research Center (MADRC) will be to facilitate innovative research into established and novel blood biomarkers, and provide expertise and access to biomarker assay technologies for investigators at the University of Michigan, Michigan State University, Wayne State University, as well as other ADRCs. The overall goal of the BC is to use cutting-edge ultrasensitive ELISA and quantitative mass spectrometry (MS) approaches to measure biomarkers in blood, identify and build novel blood-based biomarker assays, and integrate biomarkers with clinical measures of disease. We will leverage MADRC resources from ongoing and future efforts to achieve this goal and promote studies that align with the MADRC’s central theme to identify, understand and modulate the many factors beyond β-amyloid contributing to ADRD. The diverse patient population in the MADRC’s longitudinal cohort and other ongoing clinical research efforts, coupled with the ability to develop novel biomarker assays, will significantly enhance the ability of the BC to focus on unique questions regarding the extent to which current and novel biomarker targets enhance diagnostic accuracy, and track disease progression and predictability over time in multiple patient populations, including underrepresented racial/ethnic groups. The BC will pursue the following five aims: 1) provide measurements of established blood biomarkers, 2) develop and implement novel biomarker assays, 3) facilitate integration of blood biomarkers with established clinical practices to advance translational research, 4) contribute blood biomarker data to the National Alzheimer’s Coordinating Center, and 5) educate and train health care professionals, scientists and students in the use of biomarker assays. The BC goals and aims will be achieved by working closely with the MADRC Clinical Core, Data Management and Statistical Core, Neuroimaging Core, Neuropathology Core, and Research Education Component. Through these efforts, the BC will markedly enhance research supported by the MADRC, leading to a sustained and significant impact for the field as we build a comprehensive assessment of the diagnostic and the predictive utility of blood-based biomarker profiles. We will also interface with other ADRCs and investigators to help shape an evolving clinical landscape for dementia evaluation and treatment.